Latest news with #Nicotine&TobaccoResearch
Scoop
02-05-2025
- Health
- Scoop
Dr Stuart Jones Mischaracterises COPD Findings, Risks Driving Smokers Back To Cigarettes
Press Release – VIANZ A recent statement by Dr. Stuart Jones claims hard data prove that vaping alone causes COPD. A closer look at the Nicotine & Tobacco Research paper does not support Dr Joness assertions and underscores vapings potential for … A recent statement by Dr. Stuart Jones claims 'hard data' prove that vaping alone causes COPD. A closer look at the Nicotine & Tobacco Research paper does not support Dr Jones's assertions and underscores vaping's potential for harm reduction. Key Facts Baseline COPD Prevalence: Only 1.3% of exclusive e-cigarette users had COPD at enrollment, versus 2.7% of never-smokers/never-vapers – a 67% lower COPD rate in the vaping group. Incident COPD Over 3-4 Years: While vapers did develop new COPD cases at a rate 2.3-times higher than never-users (adjusted hazard ratio 2.29 [1.42–3.71]), they simply reached parity with the never-smokers/never-vapers group's higher COPD prevalence. No Evidence Vape-Driven Epidemic: End-of-study COPD prevalence in exclusive vapers mirrored the never-user group's baseline level – hardly the 'surge' implied by Dr. Jones's sound-bite. Short Follow-Up: COPD is a decades-long disease. A 3½-year window can only capture early or preexisting lung damage – not new COPD caused by vaping. Harm-Reduction Evidence: Clinical research shows that smokers with COPD who fully switch to vaping experience fewer flare-ups, improved symptoms, and stabilized lung function compared to those who continue smoking. ( and 'Cherry-picking sensational headlines over sober science does a disservice to public health,' says Jonathan Devery, Chair, Vaping Industry Association of New Zealand (VIANZ). 'Vaping is not risk-free, but for adult smokers unable to quit, it remains far less harmful than cigarettes – and misrepresenting these findings could drive people back to the most lethal form of nicotine delivery.'
Scoop
01-05-2025
- Health
- Scoop
Dr Stuart Jones Mischaracterises COPD Findings, Risks Driving Smokers Back To Cigarettes
A recent statement by Dr. Stuart Jones claims 'hard data' prove that vaping alone causes COPD. A closer look at the Nicotine & Tobacco Research paper does not support Dr Jones's assertions and underscores vaping's potential for harm reduction. Key Facts Baseline COPD Prevalence: Only 1.3% of exclusive e-cigarette users had COPD at enrollment, versus 2.7% of never-smokers/never-vapers - a 67% lower COPD rate in the vaping group. Incident COPD Over 3-4 Years: While vapers did develop new COPD cases at a rate 2.3-times higher than never-users (adjusted hazard ratio 2.29 [1.42–3.71]), they simply reached parity with the never-smokers/never-vapers group's higher COPD prevalence. No Evidence Vape-Driven Epidemic: End-of-study COPD prevalence in exclusive vapers mirrored the never-user group's baseline level - hardly the 'surge' implied by Dr. Jones's sound-bite. Short Follow-Up: COPD is a decades-long disease. A 3½-year window can only capture early or preexisting lung damage - not new COPD caused by vaping. Harm-Reduction Evidence: Clinical research shows that smokers with COPD who fully switch to vaping experience fewer flare-ups, improved symptoms, and stabilized lung function compared to those who continue smoking. ( and 'Cherry-picking sensational headlines over sober science does a disservice to public health,' says Jonathan Devery, Chair, Vaping Industry Association of New Zealand (VIANZ). 'Vaping is not risk-free, but for adult smokers unable to quit, it remains far less harmful than cigarettes - and misrepresenting these findings could drive people back to the most lethal form of nicotine delivery.'
The Independent
18-03-2025
- Health
- The Independent
Sweet nicotine pouches more addictive than other flavours, scientists warn
Sweet flavoured nicotine pouches are more likely to be consumed in high quantities by users than other varieties, researchers have warned. The number of adults who have ever used nicotine pouches has doubled since 2020 to 5.4 per cent, according to research by King's College London. Nicotine pouches are small sachets designed to be placed between the upper lips and gums. Unlike other products, such as snus, these pouches do not contain tobacco and just release nicotine slowly. But certain flavours could be more addictive than others, according to US researchers from the Yale School of Medicine. Although flavours do not significantly impact nicotine absorption, they significantly influence user satisfaction and increase the likelihood that people will continue using nicotine products. In a study published in the journal in Nicotine & Tobacco Research the effects of the sweetener's sucrose and saccharin, as well as the commonly used flavour additive cinnamaldehyde (the principal chemical of cinnamon) in nicotine were tested on rats. The researchers supplied the female and male adult Sprague Dawley rats with the various nicotine and flavour-enhanced water solutions. They found that both male and female rates significantly preferred sucrose and saccharin, but not the cinnamon flavouring. However, female rats showed the highest nicotine preference when combined with sucrose, while males preferred nicotine combined with cinnamon. When rats were given multiple options with saccharin and cinnamaldehyde, saccharin increased nicotine preference in females, but not in males. Researchers suggested that sweeteners play a greater role in nicotine preference for females, while flavours are more influential for males. They also found menthol flavouring increases oral nicotine intake in male rats, but not in female rats. 'The study examined the choice behaviours between sweetened and flavoured solutions, said the paper's lead author,' Deniz Bagdas. 'Females rats showed the highest preference for nicotine when combined with sweeteners, while males showed highest nicotine preference when combined with cinnamon. Understanding the role of sweeteners and flavourings in oral nicotine product appeal can inform regulatory policies and harm reduction strategies.' Although less harmful than smoking tobacco products, nicotine is still addictive. In a research report by the National Institute on Drug Abuse (Nida), it explains that it increases levels of dopamine in the brain's reward circuits, which motivates users to keep taking it. Once the body becomes dependent on nicotine, going without it can cause 'irritability, craving, depression, anxiety, cognitive and attention deficits', the report says.
Yahoo
05-03-2025
- Health
- Yahoo
Pray for Us Zynners
New York politicians are again targeting the finance sector—this time with a proposed ban on flavored nicotine pouches. The proposal, sponsored by state Sen. Brad Hoylman-Sigal (D–Manhattan), follows a one-two punch from Democratic Gov. Kathy Hochul to bar private equity from real estate investments and to outlaw "buy now, pay later" options on internet purchases. Nicotine pouches (including ZYN, Sesh, and Excel) deliver a buzz that keeps minds sharp and margins strong. Those in the know attest to the unparalleled edge that nicotine pouches provide. They help you lock in when you need it most: generating slide decks for client meetings, running models for your managing director, or pretending to understand what your quant just pulled from the terminal. Jokes aside, this proposal would be bad public health policy. Nicotine pouches—almond-sized packets users place between the lip and the gums—are an alternative to cigarettes and other harmful tobacco products. They contain a derived version of the nicotine compound that tobacco users crave without the carcinogenic sluff that comes with cigarettes and smokeless tobacco. Cigarettes, still popular despite declining smoking rates, are high-risk. Cigarette smoke contains at least 70 known carcinogens, including benzene and arsenic. Smokeless tobacco—chew and dip—doesn't burn, but it still contains 28 known carcinogens, dramatically increasing the risk of oral, esophageal, and pancreatic cancers. Nicotine pouches contain no tobacco leaf and no known carcinogens. They just deliver nicotine—potentially addictive, yes, but not known to be inherently harmful. Indeed, they are harm reducers, giving people who want the concentration and mood benefits of the compound an option that avoids the grave risks more traditional products pose. Last year a randomized controlled trial in the journal Nicotine & Tobacco Research concluded that pouches "show the potential" of alternative nicotine delivery systems in helping smokers kick the habit. Viewed in that context, the trebling of pouch sales in New York state since 2022 is good news. Recognizing the positive tradeoffs, the U.S. Food and Drug Administration (FDA) granted ZYN authorization in January to market its flavored pouches nationally under its premarket tobacco product application pathway "following an extensive scientific review." According to the FDA, these products met the public health standard legally required by the 2009 Family Smoking Prevention and Tobacco Control Act, which "considers the risks and benefits of products to the population as a whole." Hoylman-Sigal argues that kids will see pouches as glamorous, but there's no good evidence of that. Among American middle and high school students, tobacco use continues on a downward trend. From 2023 to 2024, the Centers for Disease Control and Prevention reports that use of any tobacco product in that age group fell from 13 percent to 10 percent. Less than 2 percent used pouches. And as with all banned substances, outlawing flavored nicotine pouches will spark a black market and create a whole new kind of derivative trading. Unless Hoylman-Sigal wants a network of finance interns smuggling arbitraged wintergreen on the PATH train from Jersey City, they ought to can this ban. The post Pray for Us Zynners appeared first on
